Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Bayer HealthCare and Regeneron Pharmaceuticals will collaborate to develop Regeneron's VEGF Trap-Eye for the treatment of eye disease. VEGF Trap-Eye is a protein that binds to or "traps" vascular endothelial growth factor, thought to play a critical role in eye disease. The drug is currently in Phase I and II clinical trials. Regeneron will get $75 million up front from Bayer and will be eligible for milestone payments of up to $245 million. The firms will jointly commercialize VEGF Trap-Eye outside the U.S.; Regeneron has all U.S. rights.
This article has been sent to the following recipient: